Economic impact of utilization of ferric carboxymaltose in patients with iron deficiency anemia in Italian regions;Impatto economico dell'utilizzo di carbossimaltosio ferrico in pazienti con anemia da carenza di ferro nelle regioni italiane

Mecosan

Volumn , Issue 93, 2015, Pages 99-114

  Rognoni, Carla ^a   Tarricone, Rosanna ^a   Meregaglia, Michela ^a  

^a BOCCONI UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944323773     PISSN: 11216921     EISSN: 23848804     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Aronoff G.R., Bennett W.M., Blumenthal S. et al. (2004). Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney International, 66: 1193-1198. DOI: 10.1111/j.1523-1755.2004.00872.x.
2. Auerbach M., Ballard H. (2010). Clinical use of intravenous iron: administration, efficacy, and safety. Hematology ASH Education Program, 4 (1): 338-347. DOI: 10.1182/asheducation- 2010.1.338.
3. Bager P., Dahlerup J.F. (2010). The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective. Journal of Crohn's and Colitis, 4 (4): 427-30. DOI: 10.1016/j.crohns.2010.01.007.
4. Charytan C., Schwenk M.H., Al-Saloum M.M. et al. (2004). Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clinical Practice, 96 (2): c63-c66. DOI: 10.1159/000076401.
5. Chertow G.M., Mason P.D., Vaage-Nilsen O. et al. (2004). On the relative safety of parenteral iron formulations. Nephrology Dialysis Transplantation, 19: 1571-1575. DOI: 10.1093/ndt/gfh185.
6. Eschbach J.W., Egrie J.C., Downing M.R. et al. (1987). Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. The New England Journal of Medicine, 316: 73-78. DOI: 10.1056/nejm198701083160203.
7. Evstatiev R., Marteau P., Iqbal T. et al. (2011). FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology, 141: 846-853 (e1-2). DOI: 10.1053/j.gastro.2011.06.005
8. Folkert V.W., Michael B., Agarwal R. et al. (2003). Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher dose (≥ 250 mg) administration. American Journal of Kidney Diseases, 41: 651-657. DOI: 10.1053/ajkd.2003.50141.
9. Fragoulakis V., Kourlaba G., Goumenos D. et al. (2012). Economic evaluation of intravenous iron treatments in the management of anemia patients in Greece. Journal of ClinicoEconomics and Outcomes Research, 4: 127-34. DOI: 10.2147/ceor. s30514
10. Gutzwiller F.S., Schwenkglenks M., Blank P.R. et al. (2012). Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. European Journal of Heart Failure, 14 (7): 782-90. DOI: 10.1093/eurjhf/ hfs083.
11. Hayat A. (2008). Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clinical Medicine and Research, 6: 93-102. DOI: 10.3121/cmr.2008.811.
12. Kulnigg S., Stoinov S., Simanenkov V. et al. (2008). A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. American Journal of Gastroenterology, 103: 1182-1192. DOI: 10.1111/j.1572-0241.2007.01744.x.
13. Moore R.A., Gaskell H., Rose P. et al. (2011). Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disorders, 11: 4. DOI: 10.1111/j.1572-0241.2007.01744.x. DOI: 10.1186/1471-2326-11-4.
14. Qunibi W.Y., Martinez C., Smith M. et al. (2010). A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysisdependent chronic kidney disease patients. Nephrology Dialysis Transplantation, 26: 1599-1607. DOI: 10.1093/ndt/gfq613.
15. Revised European Best Practice Guidelines For The Management Of Anaemia In Patients With Chronic Renal Failure. Section II: Targets For Anaemia Treatment (2004). Nephrology Dialysis Transplantation, 19 (2): S6-S15. DOI: 10.1093/ ndt/gfh1025.
16. Tagboto S., Cropper L., Turner J. et al. (2009). The efficacy of a single dose of intravenous ferric carboxymaltose (Ferinject) on anaemia in a pre-dialysis population of chronic kidney disease patients. Journal of Renal Care, 35: 18-23. DOI: 10.1111/j.1755-6686.2009.00075.x.
17. Van Wyck D.B., Roppolo M., Martinez C.O. et al. (2005). A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis- dependent CKD. Kidney International, 68: 2846-2856. DOI: 10.1111/j.1523-1755.2005.00758.x.
18. Van Wyck D.B., Martens M.G., Seid M.H. et al. (2007). Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstetrics & Gynecology, 110: 267-278. DOI: 10.1097/01.aog.0000275286.03283.18.
19. Van Wyck D.B., Mangione A., Morrison J. et al. (2009). Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion, 49: 2719-2728. DOI: 10.1111/j.1537-2995.2009.02327.x.